StockData
BeOne Medicines Ltd. logo

BeOne Medicines Ltd. (ONC) operating KPIs

ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)

Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –

BeOne Medicines prepaid R&D Costs ($M) ($M)

Form 10-Q / 10-K Prepaid Expenses Note (XBRL)

Latest, Q2 2026
48.2
Period ended Jun 30, 2026
Change on a year earlier
-36.7%
76.2 in Q2 2025
History
35 quarters
Since Q4 2017
Sources
34
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedPrepaid R&D Costs ($M) ($M)Year on yearSource
Q2 2026Jun 30, 202648.2-36.7%Form 10-Q (filed 2026-08-05) ↗
Q1 2026Mar 31, 202636.1-18.1%Form 10-Q (filed 2026-05-06) ↗
Q4 2025Dec 31, 202552.6-18.2%Form 10-Q (filed 2026-08-05) ↗
Q3 2025Sep 30, 202570+16.3%Form 10-Q (filed 2025-11-06) ↗
Q2 2025Jun 30, 202576.2+11.7%Form 10-Q (filed 2025-08-06) ↗
Q1 2025Mar 31, 202544.1-34.0%Form 10-Q (filed 2025-05-07) ↗
Q4 2024Dec 31, 202464.3+6.3%Form 10-K (filed 2026-02-26) ↗
Q3 2024Sep 30, 202460.2-17.5%Form 10-Q (filed 2024-11-12) ↗
Q2 2024Jun 30, 202468.2-5.8%Form 10-Q (filed 2024-08-07) ↗
Q1 2024Mar 31, 202466.8-12.6%Form 10-Q (filed 2024-05-08) ↗
Q4 2023Dec 31, 202360.5-15.4%Form 10-K (filed 2025-02-27) ↗
Q3 2023Sep 30, 202373-2.1%Form 10-Q (filed 2023-11-09) ↗
Q2 2023Jun 30, 202372.4-0.1%Form 10-Q (filed 2023-08-02) ↗
Q1 2023Mar 31, 202376.4-8.9%Form 10-Q (filed 2023-05-04) ↗
Q4 2022Dec 31, 202271.5-18.0%Form 10-K (filed 2024-02-26) ↗
Q3 2022Sep 30, 202274.6-1.5%Form 10-Q (filed 2022-11-09) ↗

Cite this data

StockData. (2026). BeOne Medicines Prepaid R&D Costs ($M) ($M), quarterly Q4 2017–Q2 2026 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/prepaid_rd

See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.